Try our Advanced Search for more refined results
September 15, 2010
Track this case
James L. Robart
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.Additional or older documents may be available in Pacer.
ZymoGenetics Inc. shareholders have launched a class action alleging the drug developer and Bristol-Myers Squibb are trying to lowball stockholders as they work to complete an $885 million merger.
Already a subscriber? Click here to login